Kalden J R, Manger B
Medizinische Klinik III mit Poliklinik, Friedrich-Alexander Universität Erlangen-Nürnberg, Germany.
Curr Opin Rheumatol. 1998 May;10(3):174-8. doi: 10.1097/00002281-199805000-00004.
In 1997, knowledge about the treatment of autoimmune rheumatic diseases increased further. The most promising data to date came from studies using tumor necrosis factor-alpha blocking agents, such as monoclonal antibodies or soluble receptor constructs. Clinical trials with these compounds have now advanced to phase III; however, long-term safety data are not yet available. In addition, new developments with regard to T-helper cell-directed treatment principles, anti-inflammatory cytokines, and adhesion molecules are discussed.
1997年，关于自身免疫性风湿疾病的治疗知识进一步增加。迄今为止，最有前景的数据来自使用肿瘤坏死因子-α阻断剂的研究，如单克隆抗体或可溶性受体构建体。这些化合物的临床试验现已进入III期；然而，长期安全性数据尚未可得。此外，还讨论了T辅助细胞导向治疗原则、抗炎细胞因子和黏附分子方面的新进展。
